GW Starts Study on New Type 2 Diabetes Treatment
GW Pharmaceuticals has started the first of a programme of Phase IIa exploratory clinical trials to evaluate cannabinoids as potential treatments for type 2 diabetes and metabolic syndrome.
This study programme follows promising pre-clinical research results and comprises at least three small scale clinical trials evaluating various metabolic parameters.
The first Phase IIa study to commence is a multi-centre, randomised, double blind, placebo controlled, parallel group pilot study in the treatment of dyslipidaemia in patients with type 2 diabetes.
A total of 50 patients will be divided into five treatment groups comprising four different cannabinoid formulations and placebo.
Following a 2-5 week baseline period, the treatment duration will be 13 weeks.
Thursday 30 September 2010
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment